Just In: Celgene Corporation (NASDAQ:CELG), Incyte Corporation (NASDAQ:INCY)
UBS initiates Celgene Corporation(NASDAQ:CELG) with a Buy and price target of $140. Robust top-line growth has become a rarity in large-cap biotech, and against that backdrop, Celgene has and should continue to stand out